title: Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method.
abstract: BACKGROUND
  Trimebutine maleate is a prokinetic agent that acts directly on the smooth muscle of the GI tract. A bioequivalence (BE) study of 2 oral formulations of 100 mg trimebutine maleate (TMB) was carried out in 24 healthy male Korean volunteers according to a crossover-randomized design.
  
  
  METHODS
  Subjects were given a single dose of 2 100 mg tablets of each formulation. The test and reference formulations were Recutin (Hutax Co., South Korea) and Polybutin (Samil Co., South Korea), respectively. Each set of tablets was administered with 240 ml of water to subjects after 10 h overnight fasting on 2 treatment days separated by a 1 week washout period. After dosing, serial blood samples were collected for a period of 36 h. Plasma was analyzed for the main metabolite of TMB, N-monodesmethyl trimebutine (nor-TMB), by a validated LC with MS/MS detection capacity for nor-TMB in the range 5-1500 ng/ml, with a lower limit of quantification (LLOQ) of 5 ng/ml. Several pharmacokinetic (PK) parameters (including AUC(t), AUC(infinity), C(max), T(max), T(1/2), and K(e)) were determined from the plasma concentrations of nor-TMB of both formulations. AUC(t), AUC(infinity), and C(max) were tested for BE after log-transformation of the data.
  
  
  RESULTS
  No significant difference was found based on ANOVA; 90% confidence intervals (98.98%112.03% for AUC(t); 98.60%-113.20% for AUC(infinity); 90.85%-107.87% for C(max)) for the test and reference were found within KFDA acceptance range of 80-125%.
  
  
  CONCLUSIONS
  Based on these statistical inferences, it was concluded that Recutin is bioequivalent to Polybutin and can be used interchangeably in a clinical setting.
authors.affiliation: Department of Pharmacology & Clinical Pharmacology Lab, College of Medicine & Institute of Biomedical Science, Hanyang University, Seoul 133-791, South Korea.
authors.forename: Ok Hwa
authors.initials: OH
authors.lastname: Jhee
authors.forename: Yun Sik
authors.initials: YS
authors.lastname: Lee
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Shaw
authors.forename: Yong Cheol
authors.initials: YC
authors.lastname: Jeon
authors.forename: Min Ho
authors.initials: MH
authors.lastname: Lee
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Ju Seop
authors.initials: JS
authors.lastname: Kang
mesh_terms: D000328:Adult; D002626:Chemistry, Pharmaceutical; D002853:Chromatography, Liquid; D018592:Cross-Over Studies; D005765:Gastrointestinal Agents / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D053719:Tandem Mass Spectrometry; D013810:Therapeutic Equivalency; D014287:Trimebutine / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D005765:Gastrointestinal Agents; D014287:Trimebutine